Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS patients.
- Author:
Wen-hu YAO
1
;
Wei ZHAO
;
Yin-wei WU
;
Hong ZHAO
;
Hong-xia WEI
;
Cong CHENG
;
Ping ZHU
;
Yun CHI
Author Information
- Publication Type:Journal Article
- MeSH: ADP-ribosyl Cyclase 1; biosynthesis; Acquired Immunodeficiency Syndrome; drug therapy; immunology; Adolescent; Adult; Anti-HIV Agents; therapeutic use; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Glycyrrhizic Acid; therapeutic use; HLA-DR Antigens; biosynthesis; Humans; Male; Middle Aged; T-Lymphocyte Subsets; drug effects; immunology
- From: National Journal of Andrology 2006;12(7):598-601
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo probe the effect and mechanism of Compound Glycyrrhizin in treating AIDS.
METHODSForty AIDS patients were randomly divided into a treatment group and a control group, both treated with HAART. In addition, the former was given Compound Glycyrrhizin for 6 months, and the CD4+ T count and the expressions of CD8+ and HLA-DR on the surface of peripheral blood lymphocytes (PBL) were studied before and after the treatment.
RESULTSAfter 6 months of treatment, the expressions of CD8+ and CD38+ of PBL in the treatment group [(6.6 +/- 2.1)%] were found lower than in the control [(11.4 +/- 3.8)%] (t = 5.043, P < 0.01) and CD4+ T count [(243.6 +/- 91.2) x 10(6)/L vs (170.8 +/- 55.7) x 10(6)/L] rose more significantly (t = 3.045, P < 0.01).
CONCLUSIONCompound Glycyrrhizin can lower the expression of active T-lymphocyte subset, inhibit HIV and help immune reconstitution.
